Canada Medical Device Registration Roadmap in Six Steps

1. Key takeaways

Device registration in Canada proceeds through six steps: first, the device definition and classification determination; second, MDSAP certification (Class II to IV); third, the establishment licence (MDEL); fourth, the Medical Device Licence (MDL, Class II to IV); fifth, labelling and import arrangements; sixth, bringing the post-market obligations online. Steps two and four are the two critical upstream nodes of a Class II to IV project: if step two is not complete, step four cannot be submitted.

• The classification determination at step one drives the licence path, the MDSAP requirement, the fee tier, and the label language requirement.
• MDSAP is the largest point of difference between Canada and the United States or the European Union for Class II to IV manufacturers.
• The MDEL and the MDL can be held by different entities and can proceed in parallel, but each has its own annual line to maintain.
• Post-market procedures must go live before the first shipment, not after a problem appears.

2. Legal basis

The table below lists the instruments relied upon in this article, together with the relevant provisions, dates, and official sources.

3. Expert insights

Insight one: if step one is wrong, everything downstream is reworked.

The classification determination decides whether an MDL is needed, whether MDSAP is needed, the application fee tier (643, 14,163, or 30,713 Canadian dollars), and the label language requirement, including the bilingual obligation that applies to sellers to the general public. A change of classification touches all four of these matters at once. GRZAN treats step one as an independent deliverable in its projects, so that the classification conclusion is verified and documented before the pathway, the cost, and the timeline are built on top of it.

Insight two: step two is the largest point of difference from the United States and the European Union.

The United States applies the QMSR (21 CFR 820, effective 2026-02-02, incorporating ISO 13485:2016 by reference). Canada requires Class II to IV manufacturers to hold a valid MDSAP certificate (practical estimate: mandatory since 2019-01-01). A company holding only an ISO 13485 certificate, without MDSAP, cannot start a Canadian project for Class II to IV devices. The certification is therefore not an optional add-on to the quality system work; it is the entry ticket, and its audit scope must include Canada. Projects should confirm the certificate’s validity dates and audit scope at the same time as the classification work, so that any certification gap surfaces while there is still time to close it before the licence application window.

Insight three: steps three and four can be carried by different entities, but the scheduling must be coordinated.

The MDEL is applied for by the Canadian importer or distributor, while the MDL is applied for by the foreign manufacturer. The two can be advanced in parallel, but their annual maintenance lines are independent: the MDEL Annual Licence Review falls before April 1 each year, and the MDL carries the annual right-to-sell fee of 460 Canadian dollars. A single combined calendar must capture both lines, because they sit on different provisions and follow different mechanics, and missing either one interrupts a licence that the supply chain depends on.

Insight four: step six should be live before the first shipment.

Under sections 59 to 61, the manufacturer and the importer each must submit the preliminary and final reports. Under section 63.2, Health Canada must be notified within 24 hours of a recall decision. These processes cannot be built after the first shipment has a problem. The procedures are part of the readiness of the market entry itself: the reporting channels, the responsible people, and the records must exist before commercial goods move, so that the first report can be filed on the timeline the law prescribes. A readiness review that walks through each procedure once, before the first shipment, is the cheapest way to confirm that step six is genuinely live rather than only drafted.

4. Practical recommendations

• Manage the six steps with a milestone table, assigning deliverables and responsible persons to each step.
• Make step one produce a written Classification Determination and Schedule 1 Rule Application Analysis, and use it as the input to all subsequent work.
• Schedule step two and step four in parallel, and ensure the validity period and the audit scope of the MDSAP certificate cover the application period.
• At step five, determine the language requirement under section 23: the English and French bilingual obligation is mandatory only for sales to the general public.
• Bring the four procedure sets of step six, distribution records, complaint handling, incident reporting, and recalls, online before the first shipment.
• Complete the supplier information and documented procedure corrections required under SOR/2026-110 before 2026-12-14.

5. Verification checklist

• □ Step one: the classification determination is complete, with a written record
• □ Step two: the MDSAP certificate is valid and its audit scope includes Canada (Class II to IV)
• □ Step three: the Canadian importer’s MDEL is valid
• □ Step four: for Class II to IV devices, the MDL has been obtained and has not been suspended or cancelled
• □ Step five: labels comply with sections 21 to 23, and the language requirement has been determined
• □ Step six: the four procedure sets for distribution records, complaint handling, incident reporting, and recalls are live
• □ The first shipment to Canada has not been scheduled before all six steps are complete

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Canadian market. Our team manages Health Canada Medical Device Licence and MDEL applications, prepares risk-classified dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com